International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress

Two trials verify safety, efficacy of emicizumab for haemophilia A

Audrey Abella, 20200818100000

Two trials presented at ISTH 2020 attest to the safety and efficacy of the bispecific monoclonal antibody emicizumab as a prophylactic agent in people with haemophilia A (PwHA) with factor VIII (FVIII) inhibitors.

Rates of bleeding, VTE remain low after 1-year edoxaban in real world

Low bleeding, VTE rates after 1-year edoxaban in real-world study

Pearl Toh, 20200814150010

The overall rates of bleeding and recurrent venous thromboembolism (VTE) were low across various subgroups after 12 months of edoxaban treatment in routine clinical practice, according to a non-interventional, post-authorization safety study of edoxaban — ETNA-VTE* presented during the ISTH 2020 Meeting.

Personalized TAK-660 prophylaxis may prevent bleeds in severe haemophilia A

Audrey Abella, 20200813100000

Findings from the PROPEL* trial presented at ISTH 2020 suggest that a personalized prophylaxis with rurioctocog alfa pegol (TAK-660) may prevent bleeds in patients with severe haemophilia A.

Apixaban tied to lower VTE risk in ambulatory cancer patients

Elaine Soliven, 20200813000000

Treatment with apixaban led to a significantly reduced risk of venous thromboembolism (VTE) among ambulatory cancer patients who were undergoing chemotherapy, according to two post hoc analyses of the AVERT* trial presented at the ISTH 2020 Meeting.

Thrombotic complications in COVID-19 inpatients: updates from ISTH

Pearl Toh, 20200807150010

Thrombotic complications are rife among in-hospital patients with COVID-19, with patients in the ICU particularly at risk compared with those in the general wards, a study released at the ISTH 2020 Meeting has shown.

Apixaban may confer survival benefit for COVID-19 inpatients

Pearl Toh, 20200805190000

The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.